undamentalytics Newsletter
Sign in

Biocardia, Inc. income statement

In fiscal 2025, Biocardia, Inc. reported revenue of $0, down 100.0% on the year before and net income of −$8.2m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Dec 20102011Dec 20112015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue0011011011000
Cost of revenue00—111000————
Gross profit00—−0−00001————
Research and development——236891099845
Selling, general and administrative——44666654443
General and administrative11———————————
Operating income−1−1−5−8−12−14−14−16−13−12−12−8−8
Interest expense——120—000————
Income before tax——0——————————
Income tax——00000000000
Net income−1210−7−10−12−14−15−15−13−12−12−8−8
Diluted EPS−$9.00$0.48−$51.48−$18.45−$21.75−$24.60−$1.30−$0.74−$0.38————
Diluted shares (average)1m1m1m————1m2m2m3m3m7m
EBITDA0−1−5−8−12−14−14−15−13−12−12−8−8

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Biocardia, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Biocardia, Inc.